These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 31864387)
1. Combination of the natural compound Periplocin and TRAIL induce esophageal squamous cell carcinoma apoptosis in vitro and in vivo: Implication in anticancer therapy. Han L; Dai S; Li Z; Zhang C; Wei S; Zhao R; Zhang H; Zhao L; Shan B J Exp Clin Cancer Res; 2019 Dec; 38(1):501. PubMed ID: 31864387 [TBL] [Abstract][Full Text] [Related]
2. p-Hydroxylcinnamaldehyde from cochinchinamomordica seed reverses resistance to TRAIL in human oesophageal squamous cell carcinoma via the activation of the p38 mitogen-activated protein kinase signalling pathway. Ma M; Zhang C; Xiang XH; Deng XQ; Dai SL; Wei SS; Zhang XM; Zhao LM; Liu YJ; Shan BE Biomed Pharmacother; 2020 Jan; 121():109611. PubMed ID: 31731196 [TBL] [Abstract][Full Text] [Related]
3. Antitumor Effect of Periplocin in TRAIL-Resistant gastric cancer cells via upregulation of death receptor through activating ERK1/2-EGR1 pathway. Zhao LM; Li L; Huang Y; Han LJ; Li D; Huo BJ; Dai SL; Xu LY; Zhan Q; Shan BE Mol Carcinog; 2019 Jun; 58(6):1033-1045. PubMed ID: 30737960 [TBL] [Abstract][Full Text] [Related]
4. Periplcymarin targets glycolysis and mitochondrial oxidative phosphorylation of esophageal squamous cell carcinoma: Implication in anti-cancer therapy. Han L; Xiang X; Fu Y; Wei S; Zhang C; Li L; Liu Y; Lv H; Shan B; Zhao L Phytomedicine; 2024 Jun; 128():155539. PubMed ID: 38522311 [TBL] [Abstract][Full Text] [Related]
5. Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells. Yan S; Qu X; Xu C; Zhu Z; Zhang L; Xu L; Song N; Teng Y; Liu Y J Cancer Res Clin Oncol; 2012 Aug; 138(8):1279-89. PubMed ID: 22447040 [TBL] [Abstract][Full Text] [Related]
6. Azithromycin enhances anticancer activity of TRAIL by inhibiting autophagy and up-regulating the protein levels of DR4/5 in colon cancer cells in vitro and in vivo. Qiao X; Wang X; Shang Y; Li Y; Chen SZ Cancer Commun (Lond); 2018 Jul; 38(1):43. PubMed ID: 29970185 [TBL] [Abstract][Full Text] [Related]
7. [Periplocin extracted from cortex periplocae induces apoptosis of SW480 cells through inhibiting the Wnt/beta-catenin signaling pathway]. Du YY; Liu X; Shan BE Ai Zheng; 2009 May; 28(5):456-60. PubMed ID: 19624870 [TBL] [Abstract][Full Text] [Related]
8. Prospective antitumor effects of the combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin against esophageal squamous cell carcinoma. Kondo K; Yamasaki S; Inoue N; Sugie T; Teratani N; Kan T; Shimada Y Surg Today; 2006; 36(11):966-74. PubMed ID: 17072716 [TBL] [Abstract][Full Text] [Related]
9. Naringenin up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer A549 cells. Jin CY; Park C; Hwang HJ; Kim GY; Choi BT; Kim WJ; Choi YH Mol Nutr Food Res; 2011 Feb; 55(2):300-9. PubMed ID: 20669244 [TBL] [Abstract][Full Text] [Related]
10. A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer. Huang M; Zhu H; Yi C; Yan J; Wei L; Yang X; Chen S; Huang Y Cancer Chemother Pharmacol; 2018 Nov; 82(5):829-838. PubMed ID: 30167846 [TBL] [Abstract][Full Text] [Related]
11. Upregulation of Death Receptor 5 and Production of Reactive Oxygen Species Mediate Sensitization of PC-3 Prostate Cancer Cells to TRAIL Induced Apoptosis by Vitisin A. Shin D; Kwon HY; Sohn EJ; Nam MS; Kim JH; Lee JC; Ryu SY; Park B; Kim SH Cell Physiol Biochem; 2015; 36(3):1151-62. PubMed ID: 26111475 [TBL] [Abstract][Full Text] [Related]
12. Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5. Di X; Zhang G; Zhang Y; Takeda K; Rivera Rosado LA; Zhang B Oncotarget; 2013 Sep; 4(9):1349-64. PubMed ID: 23988408 [TBL] [Abstract][Full Text] [Related]
13. 2-methoxy-5-amino-N-hydroxybenzamide sensitizes colon cancer cells to TRAIL-induced apoptosis by regulating death receptor 5 and survivin expression. Stolfi C; Caruso R; Franzè E; Rizzo A; Rotondi A; Monteleone I; Fantini MC; Pallone F; Monteleone G Mol Cancer Ther; 2011 Oct; 10(10):1969-81. PubMed ID: 21817114 [TBL] [Abstract][Full Text] [Related]
14. Thapsigargin sensitizes human esophageal cancer to TRAIL-induced apoptosis via AMPK activation. Ma Z; Fan C; Yang Y; Di S; Hu W; Li T; Zhu Y; Han J; Xin Z; Wu G; Zhao J; Li X; Yan X Sci Rep; 2016 Oct; 6():35196. PubMed ID: 27731378 [TBL] [Abstract][Full Text] [Related]
16. TRAIL induces apoptosis in oral squamous carcinoma cells--a crosstalk with oncogenic Ras regulated cell surface expression of death receptor 5. Chen JJ; Mikelis CM; Zhang Y; Gutkind JS; Zhang B Oncotarget; 2013 Feb; 4(2):206-17. PubMed ID: 23470485 [TBL] [Abstract][Full Text] [Related]
17. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer. Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930 [TBL] [Abstract][Full Text] [Related]
18. Apigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent manner. Chen M; Wang X; Zha D; Cai F; Zhang W; He Y; Huang Q; Zhuang H; Hua ZC Sci Rep; 2016 Oct; 6():35468. PubMed ID: 27752089 [TBL] [Abstract][Full Text] [Related]
19. Cisplatin-dependent upregulation of death receptors 4 and 5 augments induction of apoptosis by TNF-related apoptosis-inducing ligand against esophageal squamous cell carcinoma. Kondo K; Yamasaki S; Sugie T; Teratani N; Kan T; Imamura M; Shimada Y Int J Cancer; 2006 Jan; 118(1):230-42. PubMed ID: 16003725 [TBL] [Abstract][Full Text] [Related]
20. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction. Zhou L; Wang W; Dicker DT; Humphreys RC; El-Deiry WS Cancer Biol Ther; 2011 Aug; 12(4):335-48. PubMed ID: 21785270 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]